{
    "clinical_study": {
        "@rank": "119489", 
        "arm_group": [
            {
                "arm_group_label": "Sema", 
                "arm_group_type": "Experimental", 
                "description": "Two 12-week treatment periods separated by a wash-out period of 5-7 weeks. Finally, a follow-up visit is performed 5-7 weeks after last dosing"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the effect of\n      semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride\n      metabolism and gastric emptying in obese subjects compared with placebo."
        }, 
        "brief_title": "Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Healthy", 
            "Diabetes", 
            "Obesity"
        ], 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female, age above or equal to 18 years at the time of signing informed\n             consent\n\n          -  HbA1c (glycosylated haemoglobin A1c) below 6.5%\n\n          -  A BMI (body mass index) between 30-45 kg/m^2 (both inclusive)\n\n        Exclusion Criteria:\n\n          -  Females who are pregnant, breast-feeding or intend to become pregnant or is of\n             childbearing potential and not using adequate contraceptive method (adequate\n             contraceptive measures as required by local law or practice, UK requirements:\n             adequate contraceptive measures are defined as established use of oral, injected or\n             implanted hormonal methods of contraception, sterilisation, intrauterine device or\n             intrauterine system, or consistent use of barrier methods together with the use of\n             spermicide, and sexual abstinence)\n\n          -  Any disorder which, in the opinion of the investigator, might jeopardise subject's\n             safety or compliance with the protocol\n\n          -  Diagnosis of type 1 or 2 diabetes mellitus\n\n          -  Anticipated change in lifestyle (e.g. eating, exercise or sleeping pattern) during\n             the trial\n\n          -  Use of any prescription or non-prescription medication which could interfere with\n             trial pharmacokinetic or pharmacodynamic results, as judged by the investigator or\n             specifically: 1) within 12 months prior to screening any weight lowering\n             pharmacotherapy or pharmacotherapy that may cause weight gain, including systemic\n             corticosteroids (except for a short course of treatment, i.e., 7-10 days), tri-cyclic\n             antidepressants, atypical antipsychotic and mood stabilizers, 2) within 3 months\n             prior to screening use of statins, antihyperlipidemics including fibrates or\n             nicotinic acid and its derivates, 3) supplementation with omega 3 fatty acids from 1\n             month prior to screening, 4) co-treatment with antihypertensive drugs is allowed if\n             treatment has been stable for at least 1 month prior to screening and treatment\n             should be kept unchanged during the trial\n\n          -  Significant history of alcoholism or drug/chemical abuse within 1 year from\n             screening, or a positive result of the urine drug screen or alcohol breath test, or\n             consuming more than 21 units of alcohol per week for females and 28 units of alcohol\n             per week for males (1 unit of alcohol equals \u00bd pint [285 mL] of beer or lager, 1\n             glass [125 mL] of wine, or 1/6 gill [25 mL] of spirits)\n\n          -  Smoking or use of any nicotine products (including nicotine patches, gum etc.) in the\n             last 3 months prior to screening or a positive cotinine test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079870", 
            "org_study_id": "NN9535-3685", 
            "secondary_id": [
                "2013-000012-24", 
                "U1111-1138-2039"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Sema", 
                "description": "Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks", 
                "intervention_name": "semaglutide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Solution for subcutaneous (s.c. - under the skin) injection", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 10, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "zip": "LS2 9NG"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo", 
        "overall_contact": {
            "email": "clinicaltrials@novonordisk.com", 
            "last_name": "Novo Nordisk"
        }, 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Ad libitum energy intake during a lunch meal (following a standardised breakfast meal)", 
            "safety_issue": "No", 
            "time_frame": "After 12 weeks of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean postprandial increase (iAUC15-300min/285 min) in rating of overall appetite score (OAS) using Visual Analogue Scales (VAS) before and up to 300 minutes after intake of a standardised breakfast meal", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of treatment during a standardised meal test day"
            }, 
            {
                "measure": "Incremental area under the 0-300 minutes plasma glucose profile (iAUC0-300min,PG) following intake of a standardised breakfast meal", 
                "safety_issue": "Yes", 
                "time_frame": "After 12 weeks of treatment during a standardised meal test day"
            }, 
            {
                "measure": "Gastric emptying measured by the area under the 0-300 minutes plasma paracetamol concentration curve (AUC0-300min,para) following intake of a standardised breakfast meal (including 1500 mg paracetamol)", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of treatment during a standardised meal test day"
            }, 
            {
                "measure": "Incremental area under the 0-480 minutes plasma triglyceride profile (iAUC0-480min,TG) following intake of a standardised fat-rich meal", 
                "safety_issue": "No", 
                "time_frame": "After 12 weeks of treatment during a standardised meal test day"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "From baseline to follow-up (5-7 weeks after last trial drug administration)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}